Clinical Perspectives

large-target

An Allergist/
Immunologist

Cem Akin
MD, PHD

“Allergists are positioned to take a central role in helping patients with SM and educate other specialists on the management.”

Presentation Description

Patients may interact with many different specialists over a number of years prior to receiving a diagnosis of systemic mastocytosis. Allergy/Immunology physicians play an important role due to their unique perspectives on diagnosing and treating patients with systemic mastocytosis.

This module discusses key topics related to diagnosis and treatment of systemic mastocytosis, including clinical manifestations, workup, treatment options, and a summary of unmet needs, as told from the perspective of an Allergist/Immunologist.

Video Description

Watch Dr. Cem Akin’s presentation on behalf of Blueprint Medicines from the 2021 American Academy of Allergy, Asthma, & Immunology (AAAAI) annual meeting to learn more about systemic mastocytosis.

poly-lines-bg

Presentation Description

Patients may interact with many different specialists over a number of years prior to receiving a diagnosis of systemic mastocytosis. Allergy/Immunology physicians play an important role due to their unique perspectives on diagnosing and treating patients with systemic mastocytosis.

This module discusses key topics related to diagnosis and treatment of systemic mastocytosis, including clinical manifestations, workup, treatment options, and a summary of unmet needs, as told from the perspective of an Allergist/Immunologist.

Cem Akin
MD, PHD

“Allergists are positioned to take a central role in helping patients with SM and educate other specialists on the management.”

Video Description

Watch Dr. Cem Akin’s presentation on behalf of Blueprint Medicines from the 2021 American Academy of Allergy, Asthma, & Immunology (AAAAI) annual meeting to learn more about systemic mastocytosis.

AAAAI 2021

Blueprint Medicines and associated logos are trademarks of Blueprint Medicines Corporation.
© 2021 Blueprint Medicines Corporation.
07/2021 USBP-PRSM-20.001.2